AdvisorShares Psychedelics ETF Rating $24.59 -0.23 (-0.93%) As of 04:10 PM Eastern Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsNews and TrendsOwnershipRatings AdvisorShares Psychedelics ETF Aggregate Rating and Price Target (2026)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.PSIL Aggregate RatingModerate Buy 2.62Holdings in PSIL have an aggregate rating of Moderate Buy based on 237 analyst ratings issued in the past year covering 19 companies (81.2% of the portfolio).PSIL Aggregate Price Target$24.59High Prediction$24.59Average Prediction$24.59Low Prediction$24.59Holdings in PSIL have an aggregate price target of $24.59 and a range of $24.59 to $24.59 covering 19 companies (81.2% of the portfolio).PSIL Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy1 Buy rating(s)Moderate Buy12 Moderate Buy rating(s)Hold5 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell1 Strong Sell rating(s) Ratings for Stocks Held by AdvisorShares Psychedelics ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 19 PSIL Holdings ExportWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings11.40%CMPSCompass Pathways$13.29+0.5%2.0411 of 5 stars2.88$23.36 75.7%17Analyst Upgrade11.35%ATAIAtai Beckley$7.34-0.1%2.8294 of 5 stars2.06$10.56 43.8%16High Trading Volume11.30%DFTXDefinium Therapeutics$38.00-2.3%3.8579 of 5 stars3.00$63.00 65.8%204.90%ANROAlto Neuroscience$36.17-1.3%1.1745 of 5 stars2.64$37.25 3.0%114.82%NRXPNRx Pharmaceuticals$3.43-0.9%1.9434 of 5 stars2.43$34.50 905.8%74.39%GHRSGH Research$27.92-0.5%2.9309 of 5 stars2.75$45.00 61.2%12Positive News4.34%STIMNeuronetics$2.72-1.8%4.0279 of 5 stars2.50$4.50 65.4%4Positive News4.12%ABBVAbbVie$260.69-0.4%4.6091 of 5 stars2.88$275.95 5.9%26Trending NewsAnalyst Revision4.06%RLMDRelmada Therapeutics$4.37-3.7%2.2802 of 5 stars2.75$12.00 174.6%83.78%NBIXNeurocrine Biosciences$158.35+0.4%4.9322 of 5 stars2.88$201.05 27.0%24Positive NewsAnalyst Forecast3.67%JNJJohnson & Johnson$278.66+1.3%4.5737 of 5 stars2.80$272.83 -2.1%25Trending NewsAnalyst ForecastAnalyst Revision3.62%ALKSAlkermes$46.88-1.8%2.4729 of 5 stars2.72$54.56 16.4%18Insider Trade2.69%SUPNSupernus Pharmaceuticals$43.97-0.1%4.516 of 5 stars2.71$62.83 42.9%7Positive News1.97%NEUPNeuphoria Therapeutics$3.76+0.3%2.8775 of 5 stars2.00$21.00 458.5%4Short Interest DecreaseGap Up1.58%LLYEli Lilly and Company$1,160.98+0.1%4.9235 of 5 stars2.83$1,292.18 11.3%30Trending NewsAnalyst Upgrade1.26%PBMPsyence Biomedical$4.43+1.4%1.128 of 5 stars1.0011.06%KTTAPasithea Therapeutics$0.58+0.0%2.4688 of 5 stars2.00$3.00 416.9%3News CoverageGap Up0.46%IXHLIncannex Healthcare$3.25-0.6%1.7461 of 5 stars2.00$18.00 453.8%20.42%IGCIGC Pharma$0.30+0.9%2.7795 of 5 stars2.50$5.50 1,742.5%2Analyst Revision This page (NYSEARCA:PSIL) was last updated on 9/3/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AdvisorShares Psychedelics ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share AdvisorShares Psychedelics ETF With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
